In light of the increased number and activation of tumor infiltrating CD8 T cells in SD101-treated mice, we tested their role in treated and untreated contralateral lesions in tumor bearing mice, either immune competent (BALB/c mice) or immune-deficient (nu/nu). The gene discussed is CD8A; the disease is neoplasm.